News

MetroMRT contributes to clinical trial of cancer treatment

The chemical structure of selumetinib

Results of EMRP project MetroMRT (HLT11) implemented in first clinical trial with image-based dosimetry

One of the calibration protocols developed with funding from EMRP project 'Metrology for molecular radiotherapy' MetroMRT and the UK National Measurement and Regulation Office (NMRO) is being used for implementation of dosimetry in a new clinical trial - the first to use image-based dosimetry.

The Cancer Research UK funded clinical trial, SEL-I-METRY, is investigating the potential use of the drug selumetinib to resensitise thyroid cancers which have stopped responding to radioiodine therapy. Patients are expected to be recruited in January 2016.

Molecular radiotherapy (MRT) has the potential to become a valuable tool in the treatment of cancer. However, widespread MRT use is being hampered by a reluctance to adopt individual patient-tailored dosimetry, which is perceived to be difficult and resource intensive.

The MetroMRT project 'Metrology for molecular radiotherapy' developed the metrology needed to support routine use of individual MRT patient dosimetry, and working with the MRT community to develop standard procedures incorporating both calibration and verification.

Select your area of interest